Skip to content

Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch – CNBC

Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch – CNBC

 

 Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at… 

Read More